Head to Head Review: ALT5 Sigma (AIFC) versus The Competition

ALT5 Sigma (NASDAQ:AIFC) is one of 345 public companies in the “Financial Services” industry, but how does it weigh in compared to its competitors? We will compare ALT5 Sigma to related businesses based on the strength of its dividends, analyst recommendations, valuation, earnings, institutional ownership, profitability and risk.

Analyst Recommendations

This is a breakdown of recent recommendations for ALT5 Sigma and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALT5 Sigma	1	0	0	0	1.00
ALT5 Sigma Competitors	1900	6813	11512	414	2.51

As a group, “Financial Services” companies have a potential upside of 4.15%. Given ALT5 Sigma’s competitors stronger consensus rating and higher probable upside, analysts clearly believe ALT5 Sigma has less favorable growth aspects than its competitors.

Valuation and Earnings

This table compares ALT5 Sigma and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
ALT5 Sigma	$24.84 million	-$344.51 million	1.33
ALT5 Sigma Competitors	$6.28 billion	$1.07 billion	10.34

ALT5 Sigma’s competitors have higher revenue and earnings than ALT5 Sigma. ALT5 Sigma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares ALT5 Sigma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ALT5 Sigma	-4,021.65%	-51.87%	-48.30%
ALT5 Sigma Competitors	-405.72%	-21.94%	-5.68%

Volatility & Risk

ALT5 Sigma has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, ALT5 Sigma’s competitors have a beta of 2.26, suggesting that their average share price is 126% more volatile than the S&P 500.

Insider and Institutional Ownership

6.3% of ALT5 Sigma shares are held by institutional investors. Comparatively, 43.0% of shares of all “Financial Services” companies are held by institutional investors. 0.2% of ALT5 Sigma shares are held by company insiders. Comparatively, 21.9% of shares of all “Financial Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

ALT5 Sigma competitors beat ALT5 Sigma on 13 of the 13 factors compared.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.